Nanjing Huawe Medicine Technology Development Co., Ltd.

Posaconazole enteric-coated tablets (100 mg) produced by Kangyuan Huawei Pharmaceuticals Co., Ltd. were used as the test preparation, and NOXAFIL® (100 mg) marketed by Merck Sharp & Dohme Ltd was used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after single administration in the fasting and postprandial states were investigated to evaluate whether the two preparations were bioequivalent, and the safety of the two preparations in healthy subjects was evaluated.

Primary objective: To evaluate the effectiveness of levopantoprazole sodium injection in the treatment of acute upper gastrointestinal ulcer bleeding by comparing with pantoprazole sodium injection. Secondary objective: To evaluate the safety of levopantoprazole sodium injection in the treatment of acute upper gastrointestinal ulcer bleeding by comparing with pantoprazole sodium injection.

To evaluate the safety and efficacy of clevidipine butyrate fat emulsion injection in the treatment of patients with hypertensive emergencies, using nicardipine hydrochloride injection as a control.